$50 Million
Sole Bookrunner
Follow-On
May 2016
$124 Million
Joint Bookrunner
Initial Public Offering
May 2016
$115 Million
Joint Bookrunner
Follow-On
April 2016
$190 Million
Co-Manager
Initial Public Offering
April 2016
$85 Million
Exclusive Financial Advisor
Sale to Allergan
April 2016
Undisclosed
Exclusive Financial Advisor
Sale to Alvogen
April 2016
$144 Million
Joint Bookrunner
Follow-On
April 2016
$49 Million
Joint Bookrunner
Follow-On
March 2016
$185 Million
Exclusive Financial Advisor
Acquisition of US Contrave Rights from Takeda
March 2016
Undisclosed
Exclusive Financial Advisor
European Commercialization Agreement with Valeant
March 2016
$165 Million
Exclusive Financial Advisor
Senior Secured Convertible Notes
March 2016
$50 Million
Joint Bookrunner
Initial Public Offering
February 2016